...
首页> 外文期刊>BMC Women s Health >Hysteropexy in the treatment of uterine prolapse stage 2 or higher: a multicenter randomized controlled non-inferiority trial comparing laparoscopic sacrohysteropexy with vaginal sacrospinous hysteropexy (LAVA-trial, study protocol)
【24h】

Hysteropexy in the treatment of uterine prolapse stage 2 or higher: a multicenter randomized controlled non-inferiority trial comparing laparoscopic sacrohysteropexy with vaginal sacrospinous hysteropexy (LAVA-trial, study protocol)

机译:子宫切除术在子宫脱垂的2期或更高阶段的治疗:一项多中心随机对照非劣效性试验,比较了腹腔镜sa行子宫切除术与阴道sa棘下子宫切除术(LAVA试验,研究方案)

获取原文
           

摘要

Background Pelvic organ prolapse is a common health problem: the lifetime risk of undergoing surgery for pelvic organ prolapse by the age of 85 years is 19%. Pelvic organ prolapse has significant negative effects on a woman’s quality of life. Worldwide, vaginal hysterectomy is the leading treatment method for patients with symptomatic uterovaginal prolapse. Several studies have shown that vaginal sacrospinous hysteropexy and laparoscopic sacrohysteropexy are safe and effective alternatives in treating uterine descent. To date, it is unclear which of these techniques leads to the best operative result and the highest patient satisfaction. Therefore, we conducted the LAVA trial. Methods The LAVA trial is a randomized controlled multicenter non-inferiority trial. The study compares laparoscopic sacrohysteropexy with vaginal sacrospinous hysteropexy in women with uterine prolapse stage 2 or higher. The primary outcome of this study is surgical success of the apical compartment at 1 and 5 years follow-up. Secondary outcomes are subjective improvement on urogenital symptoms and quality of life (assessed by disease-specific and general quality of life questionnaires), complications following surgery, hospital stay, post-operative recovery, sexual functioning and costs-effectiveness. Evaluation will take place pre-operatively, and 6 weeks, 6 months, 12 months and annually till 60 months after surgery. Validated questionnaires will be used. Analysis will be performed according to the intention to treat principle. Based on comparable recurrence rates of 3% and a non-inferiority margin of 10%, 62 patients are needed in each arm to prove the hypothesis with a 95% confidence interval. Discussion The LAVA trial is a randomized controlled multicenter non-inferiority trial that will provide evidence whether the efficacy of laparoscopic sacrohysteropexy is non-inferior to vaginal sacrospinous hysteropexy in women with symptomatic uterine prolapse stage 2 or higher. Trial registration Netherlands Trial Register (NTR): NTR4029
机译:背景技术盆腔器官脱垂是一个常见的健康问题:到85岁时,一生接受盆腔器官脱垂手术的终生风险为19%。盆腔器官脱垂对女性的生活质量有严重的负面影响。在世界范围内,阴道子宫切除术是有症状子宫阴道脱垂患者的主要治疗方法。几项研究表明,阴道sa棘子宫切除术和腹腔镜sa子宫切除术是治疗子宫下降的安全有效的替代方法。迄今为止,尚不清楚这些技术中的哪一种可导致最佳的手术效果和最高的患者满意度。因此,我们进行了LAVA试验。方法LAVA试验是一项随机对照的多中心非劣效性试验。这项研究比较了子宫脱垂2期或更高的妇女的腹腔镜下子宫穿刺术和阴道sa上子宫穿刺术。这项研究的主要结果是在1和5年的随访中根尖室的手术成功。次要结果是泌尿生殖器症状和生活质量的主观改善(通过疾病特异性和总体生活质量调查表评估),手术后的并发症,住院,术后恢复,性功能和成本效益。评估将在术前,术后6周,6个月,12个月进行,每年至术后60个月进行。将使用经过验证的问卷。将根据治疗意图原则进行分析。基于3%的可比较复发率和10%的非劣效性,每组需要62名患者以95%的置信区间证明该假设。讨论LAVA试验是一项随机对照的多中心非劣效性试验,将为有症状子宫脱垂至2级或更高的女性提供腹腔镜scopic行子宫穿刺术的疗效是否不低于阴道sa上子宫输卵管检查的证据。试用注册荷兰试用注册(NTR):NTR4029

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号